Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lesaka Technologies Q1 FY2026 Earnings Call - Strong Growth and Strategic Integration Across Divisions
Lesaka Technologies reported robust results in Q1 FY2026, hitting the lower end of revenue guidance at ZAR 1.53 billion, up 45% year-on-year, and delivering group adjusted EBITDA of ZAR 271 million, a...
- Lesaka Technologies met its guidance for the 13th consecutive quarter with Q1 FY2026 revenue at ZAR 1.53 billion, up 45% YoY.
- Group adjusted EBITDA reached ZAR 271 million, marking a 61% year-on-year increase, reflecting improved earnings quality with fewer non-recurring items.
- Adjusted earnings doubled to ZAR 1.7 per share from ZAR 0.54, indicating strengthened profitability per share.
- +12 more takeaways
Commerce Third Quarter 2025 Earnings Call - AI Integration and Product Innovation Drive Solid Performance with Focus on Profitable Growth
Commerce, formerly BigCommerce, reported Q3 2025 revenue of $86 million, aligning with guidance, and posted non-GAAP operating income of $8 million, exceeding expectations. The company highlights AI a...
- Q3 2025 revenue reached $86 million, in line with guidance, with non-GAAP operating income of $8 million surpassing expectations.
- Annual revenue run rate approximated $356 million, with 76% from enterprise accounts, average revenue per enterprise account up 7% year-over-year.
- Feedonomics is central to Commerce’s AI strategy, syndicating enriched product data to AI platforms like OpenAI, Google Gemini, and Perplexity.
- +12 more takeaways
Apyx Medical Q3 2025 Earnings Call - Aon Launch Drives Surgical Aesthetics Growth and Updated Revenue Guidance
Apyx Medical's third quarter of 2025 marked a pivotal step in its transformation with the successful launch of the Aon body contouring system, driving a 19% revenue increase in its newly rebranded sur...
- Apyx Medical rebranded its advanced energy segment to surgical aesthetics to better align with its evolving business focus.
- Third quarter 2025 total revenue increased 12% year-over-year to $12.9 million, driven primarily by surgical aesthetics product sales.
- Surgical aesthetics revenue rose 19% to $11.1 million, thanks chiefly to the successful commercial launch of the Aon body contouring system.
- +12 more takeaways
Collegium Pharmaceutical 3Q 2025 Earnings Call - Robust Jornay PM Growth and Durable Pain Portfolio Drive Raised Guidance
Collegium Pharmaceutical delivered a strong third quarter in 2025, with total net revenues reaching a record $209.4 million, up 31% year-over-year, driven by significant growth in Jornay PM and sustai...
- Collegium Pharmaceutical achieved record quarterly net revenues of $209.4 million in Q3 2025, a 31% increase year-over-year.
- Jornay PM net revenues hit $41.8 million with prescriptions growing 20% year-over-year, marking it as the fastest-growing ADHD stimulant.
- Jornay's market share in long-acting branded methylphenidate increased to 23.4%, up 6.3 percentage points from a year ago.
- +10 more takeaways
Lantheus 3Q 2025 Earnings Call - Leadership Transition and Strategic Expansion Fuel Confidence Amid Market Stabilization
Lantheus reported a mixed third quarter with total revenues up slightly, driven by Precision Diagnostic growth, while Radiopharmaceutical Oncology revenues, led by Polarify, declined 7%. The company f...
- CEO Brian Markison will retire at the end of 2025; Mary Anne Heino, former CEO and current Board Chair, will serve as interim CEO to ensure a smooth leadership transition.
- Lantheus narrowed 2025 full-year revenue guidance to $1.49-$1.51 billion and adjusted EPS to $5.50-$5.65, reflecting ongoing execution and market dynamics.
- Polarify sales fell 7% year-over-year to $240.6 million despite a 3.3% volume increase; pricing pressures and 340B resets continue to weigh on revenue.
- +12 more takeaways
Esperion Therapeutics 3Q 2025 Earnings Call - Strong Revenue Growth and Strategic Positioning for 2026 Profitability
Esperion Therapeutics reported a robust third quarter in 2025, with total revenue surging 69% year-over-year to $87.3 million. U.S. net product revenue rose 31% to $40.7 million, driven by nearly doub...
- Total revenue for Q3 2025 grew 69% year-over-year to $87.3 million, with U.S. net product revenue up 31% to $40.7 million.
- Sequential quarterly prescription growth in the U.S. reached nearly double digits despite one-time patient access program costs.
- Four generic manufacturers agreed not to market competing generic versions of Nexletol and Nexlizet prior to April 2040, extending IP protection significantly.
- +10 more takeaways
Ispire Technologies Q1 2026 Earnings Call - Strategic Shift Strengthens Financials Despite Revenue Drop
Ispire Technologies delivered mixed results for its first fiscal quarter of 2026, marked by a deliberate pivot away from cannabis customers toward higher-quality clients in the nickel vaping sector. T...
- Ispire Technologies reported Q1 fiscal 2026 revenue of $3.4 million, down 63% year over year due to exiting the cannabis sector.
- Operating expenses fell sharply by 39% to $7.8 million, reflecting aggressive cost control measures.
- Net loss improved to $3.3 million from $5.6 million, indicating better financial discipline and focus on profitability.
- +9 more takeaways
Enact Q3 2025 Earnings Call - Upgraded Capital Return Guidance Amid Stable Credit and Expense Discipline
Enact reported solid third-quarter 2025 results with adjusted operating income of $166 million and a 13% return on equity, reflecting disciplined execution amid a shifting macroeconomic landscape. The...
- Enact delivered adjusted operating income of $166 million and $1.20 per diluted share in Q3 2025.
- Adjusted return on equity was 13%, insurance in force rose 2% year-over-year to $272 billion, with new insurance written exceeding $14 billion.
- The company increased 2025 capital return guidance to approximately $500 million from $400 million, reflecting confidence in strong business results and mortgage origination levels.
- +7 more takeaways
Privia Health Q3 2025 Earnings Call - Strong Value-Based Care Growth and Elevated Profitability Drive Raised 2025 Outlook
Privia Health demonstrated strong operational and financial execution in Q3 2025, fueling raised full-year guidance. Implemented provider growth surged 13.1% year-over-year while value-based care attr...
- Privia Health grew implemented providers 13.1% year-over-year to 5,250 by September 30, 2025.
- Value-based attributed lives increased nearly 13% year-over-year, with commercial lives rising 12% and Medicare Advantage lives up over 12%.
- Practice collections in Q3 rose 27.1% year-over-year to $940.4 million, boosted by growth in new markets (including Arizona) and strong fee-for-service utilization.
- +13 more takeaways
Harvard Bioscience Q3 2025 Earnings Call - Operational Progress and Strong Backlog Amid Refinancing Efforts
Harvard Bioscience reported $20.6 million in Q3 2025 revenue, hitting the high end of guidance with a modest sequential increase in a typically soft quarter. Gross margin expanded to 58.4%, driven by ...
- Harvard Bioscience delivered $20.6 million revenue in Q3 2025, at the high end of their guidance and up slightly sequentially despite typical Q3 softness.
- Gross margin improved to 58.4%, exceeding guidance and reflecting better product mix and operational efficiency.
- Adjusted EBITDA increased to $2 million, driven by expense reductions offsetting lower year-over-year revenue.
- +12 more takeaways